Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Edward Apicella

Interventional Pain Medicine Albany, NY Medical Doctor

NPI 1528051869 CMS profile 250336

12 Corporate Woods Blvd, Albany, NY 12211

Open in the dashboard

General payments

$12,720

185 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Edward Apicella of Albany, NY is reported in the CMS Open Payments database as having received $12,720 across 185 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $151 2
2022 General $300 9
2021 General $606 17
2020 General $3,578 56
2019 General $8,086 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Apicella
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Edward Apicella were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Edward Apicella Interventional Pain Medicine median Middle half National median
2019 $8,086 $684 $216–$2,079 $163
2020 $3,578 $382 $122–$1,109 $114
2021 $606 $552 $167–$1,554 $132
2022 $300 $605 $187–$1,924 $149
2023 $151 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abbott Laboratories $8,127 47 payments
  2. Nevro Corp. $2,229 40 payments
  3. Boston Scientific Corporation $1,198 32 payments
  4. Medtronic USA, Inc. $242 27 payments
  5. Scilex Pharmaceuticals Inc. $186 11 payments
  6. Biohaven Pharmaceuticals, Inc. $158 3 payments
  7. Relievant Medsystems, Inc. $146 2 payments
  8. Flexion Therapeutics, Inc. $62 3 payments
  9. Horizon Therapeutics plc $58 4 payments
  10. Allergan Inc. $51 3 payments
  11. Other $264 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,616 182 payments
  2. Consulting Fee $6,104 3 payments
Products named General payments · program years 2019–2023
  1. Proclaim Family of SCS IPGs $5,707 18 payments
  2. Senza Spinal Cord Stimulation System $1,964 36 payments
  3. Neuromodulation Dspsbls and Accs $1,391 2 payments
  4. SPECTRA WAVEWRITER $688 18 payments
  5. Octrode SCS Leads $478 10 payments
  6. GENERAL PAIN MANAGEMENT $450 12 payments
  7. Prodigy Family of SCS IPGs $202 6 payments
  8. ADAPTIVESTIM $170 19 payments
  9. NURTEC ODT $158 3 payments
  10. Intracept $146 2 payments
  11. Other $1,665 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record